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Phylogenetic approach reveals that virus genotype largely
determines HIV set-point viral load
Abstract
HIV virulence, i.e. the time of progression to AIDS, varies greatly among patients. As for other rapidly
evolving pathogens of humans, it is difficult to know if this variance is controlled by the genotype of the
host or that of the virus because the transmission chain is usually unknown. We apply the phylogenetic
comparative approach (PCA) to estimate the heritability of a trait from one infection to the next, which
indicates the control of the virus genotype over this trait. The idea is to use viral RNA sequences
obtained from patients infected by HIV-1 subtype B to build a phylogeny, which approximately reflects
the transmission chain. Heritability is measured statistically as the propensity for patients close in the
phylogeny to exhibit similar infection trait values. The approach reveals that up to half of the variance in
set-point viral load, a trait associated with virulence, can be heritable. Our estimate is significant and
robust to noise in the phylogeny. We also check for the consistency of our approach by showing that a
trait related to drug resistance is almost entirely heritable. Finally, we show the importance of taking
into account the transmission chain when estimating correlations between infection traits. The fact that
HIV virulence is, at least partially, heritable from one infection to the next has clinical and
epidemiological implications. The difference between earlier studies and ours comes from the quality of
our dataset and from the power of the PCA, which can be applied to large datasets and accounts for
within-host evolution. The PCA opens new perspectives for approaches linking clinical data and
evolutionary biology because it can be extended to study other traits or other infectious diseases.
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Introduction
One of the hallmarks of HIV infection is the enormous variation
in disease progression. While some untreated patients survive for
more than 25 years, others die within a year of infection [1].
Delineating what fraction of this variation is attributable to host
versus virus genotype has important clinical and epidemiological
applications. Whole genome association studies showed that at
least 15% of the variations in traits associated with disease
progression in HIV can be explained by common host genetic
variants [2,3]. In this study, we adopt a new approach to quantify
the contribution of the viral genotype to disease progression.
The natural course of an HIV infection is divided into three
clinical stages: the acute phase, which lasts for several weeks; the
asymptomatic phase, which can last several years; and the AIDS
phase, which can last several months to a few years and ends with
the death of the patient. The effect of the HIV viral genotype on
disease progression is debated. Arguably, this is due to the fact
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that, as for most infectious diseases of humans, it is difficult to
determine the transmission chain (i.e. ‘Who infected whom?’).
Early studies showed that long times to AIDS are associated with
the receipt of blood from donors who developed AIDS late [4,5].
A study found a strong correlation between maternal and infant
viral load [6], but mother-to-child transmission introduces
confounding factors through host genetic relatedness. In some
cases, transmission pairs are known and one can then measure the
heritability of traits from one infection to the next. This heritability
corresponds to the fraction of the variance among patients that is
explained by the virus genotype [7,8]. Studies found that 21% [9],
23% [8], 25% [10] and 55% [11] of the variance in set-point viral
load (spVL) can be explained by the virus genotype. These studies
suggest that infection traits can be heritable but the accuracy of
their estimates is likely to be limited by the sample size of the data
and the accuracy of their spVL measurement.
The phylogenetic comparative approach (PCA) allows to
estimate the phylogenetic signal for a trait measured in several
species if the species’ phylogeny is known. This signal indicates the
extent to which the phylogeny explains observed trait values (see
the Methods). Several studies show that this signal is very similar to
heritability [12,13], which we also verify in this study. Here, we
use this classical evolutionary biology method [14] to address
epidemiological questions.
We consider the case of HIV infection traits using the data from
the Swiss HIV Cohort Study (SHCS [15]). As the majority of
previous studies [2,3,6,8,9,16,17], we focus on the set-point viral
load (spVL, see the Methods) measured during the asymptomatic
phase of an HIV infection because it has been shown to be
associated with the time to AIDS, i.e. virulence [16,18–20]. The
quality of the SHCS patient data allows us to have a better
estimation of spVL than many studies that often rely on single viral
load measurements to estimate spVL (see the Materials and
Methods). Further, we consider the decline slope of the CD4z T-
cells (dsCD4), which also predicts virulence [21], but to a smaller
extent than spVL [20].
We use sequences of the HIV pol gene isolated from infected
patients to build a phylogenetic tree, where each leaf corresponds
to a patient whose trait values are known (Figure 1). Proximity in
the resulting tree reflects proximity in the transmission chain
[22,23] but we emphasise that the phylogeny is only an
approximation of the true transmission history. As we will show
later on, our approach has the advantage of being robust to this
noise in the phylogeny. We then quantify phylogenetic signal for
each of the traits on the tree [24]. In addition to log(spVL) and
dsCD4, we study a third trait as a control: the probability for
resistance to zidovudine (AZT), denoted prAZT. We expect the
latter trait to be strongly heritable because it is evaluated from the
virus pol sequence. Note that there is no overlap between the
information used to build the phylogeny and that used to evaluate
prAZT (see the Methods).
We split the data into 4 datasets using 2 criteria. First, in
addition to the ‘strict’ definition used in previous studies to define
spVL from multiple viral load measurements [2,3], we also
consider a ‘liberal’ definition (see the Methods). The strict
definition is known to improve the accuracy of the spVL measure
and we want to assess the importance of the quality of this estimate
on our ability to detect heritability. Second, we study one of the
transmission groups (‘men having sex with men’, or MSM)
separately. This group is likely to yield a more accurate phylogeny
because of denser sampling in the SHCS [25]. We show in
Supplementary Results (Text S1) that focusing on these datasets
also removes some of the confounding factors, such as patient sex,
transmission group or age, on infection trait values.
We quantify phylogenetic signal using two estimators (denoted
K [12] and l [26]) that are based on two different methods to
better detect potential artifactual values (see the Methods). A signal
value of 0 implies that the phylogeny does not contain any
information to explain the variance of the trait in the population.
Conversely, a signal value of 1 means that the distance between
tips in the phylogeny used best explains the tip data assuming a
Brownian model of evolution of the trait on the tree.
Results
Trait heritability
We first present the results obtained with the ‘MSM strict’
dataset. This dataset is the smallest we study. It has the advantage
of relying on the criterion for spVL already used by earlier studies
and of minimising noise in the data linked with transmission
groups. The estimator for phylogenetic signal K reveals a
significantly high signal for log(spVL) (K~0:59, Table 1). The
standard deviation estimated from the bootstrapped trees is 0:07.
As explained above, uncertainty is inherent to any HIV
phylogeny. Therefore, one might argue that the value we find is
underestimated because of the noise in the phylogeny. Improving
a phylogeny is a difficult task but making it worse is easy. We thus
check for the robustness of the value of K by introducing errors in
the phylogeny in two ways. The first way consists in measuring K
on the bootstrapped trees, which are by definition less accurate
than the consensus tree. The second way consists in swapping 3,
10 or 20% of the tip values at random. As shown in the
Supplementary Results, on average considering the trees from the
bootstrap or trees with errors does not significantly affect the signal
intensity (i.e. the value of K ): with more noise, the value of K
remains constant but the significance level decreases.
The intensity of the signal strongly decreases when we use the
liberal criterion for spVL (K~0:09 in the ‘MSM liberal’ dataset),
which highlights the importance of the accuracy of the spVL
estimate. The signal even becomes non-significant when we
consider all the transmission groups. This can be explained by the
fact that, in the SHCS, patients from the MSM transmission group
tend to cluster on a phylogeny and are more densely sampled than
patients from other transmission groups (see the Methods). As a
Author Summary
Some untreated patients infected by HIV die within a
couple of years, while others survive more than 25 years.
To date, it is still unclear whether this variance in the
virulence of the infection is due to the host or to the virus
genotype. One of the main difficulties in answering this
question is that, as for most human diseases, we tend not
to know who infected whom. Here, we solve this problem
by adopting a phylogenetic approach, which estimates the
heritability of species traits on a phylogeny. In our case,
species correspond to infected patients and the trait is an
infection trait. The phylogeny is obtained from the HIV
RNA sequences isolated in each patient. We find that more
than half of the variance observed in the set-point viral
load—a trait that predicts virulence—is heritable from one
infection to the next. This implies that set-point viral load is
strongly controlled by the virus genotype. This application
of the phylogenetic comparative approach to infectious
diseases yields major results for the deciphering of HIV
pathogenesis. Future applications to other traits and/or
other pathogens will help us to better understand rapidly
evolving diseases of humans.
Heritability of HIV Infection Traits
PLoS Pathogens | www.plospathogens.org 2 September 2010 | Volume 6 | Issue 9 | e1001123
consequence, a phylogeny built only on sequences from MSM
patients is likely to be closer to the transmission chain. Also, using
the liberal criterion or considering all the transmission groups
means that log(spVL) is affected by confounding factors.
Results show no phylogenetic signal for dsCD4 in all datasets
(Table 1). A possibility is that CD4 densities vary strongly within
patients on short time scales. However, even a less variable
estimate, the decline slope of the ratio of CD4z to CD8z T-cells,
did not exhibit significant phylogenetic signal. This suggests that
this trait is not directly affected by the viral genotype or that the
effect is too weak to be detected.
For prAZT in the MSM strict dataset, we find K~0:91 (with a
standard deviation on bootstrapped trees of 0.084). As for the
log(spVL), this result is robust to noise in the phylogeny (see
Supplementary Results). Using the liberal criterion has little effect
on this value (K~0:82 in the MSM lib dataset), which is consistent
with the fact that drug resistance is genetically determined. The
drop in heritability is likely to be a consequence of the increase in
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Figure 1. Combining phylogenies and trait values in the MSM strict dataset. A) A phylogeny based on HIV sequences obtained from
patients with known set-point viral loads, B) Phylogenetic distance between two tips versus difference in trait value between these two tips
(slope~2:2 and p-valuev0:001) and C) Distribution of log(spVL) values in the MSM strict dataset. Panel A shows the maximum likelihood
phylogenetic tree built with the MSM strict dataset. Squares on the tips of the tree correspond to infected patients. The colour of the squares and the
graph on the right indicate the set-point viral load (colours range from blue to red for increasing log(spVL)). The PCA tests the correlation between
proximity in the phylogeny and trait values (log(spVL)). The circles on the tree nodes indicate bootstrap values: black is greater than 90%, grey is
between 50 and 90% and white is lower than 50%.
doi:10.1371/journal.ppat.1001123.g001
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tree size, which decreases the accuracy of K (see Supplementary
Results). When we consider all the transmission groups, we find a
non-significant value for the strict dataset and K~0:71 in the
liberal dataset. This could be due to the fact that average prAZT is
higher in one of the transmission groups (injection drug users) and
to the fact that a phylogeny built with MSM patients better reflects
the transmission chain.
We also perform these measures using a different estimator for
phylogenetic signal, l [26]. Results are similar to those found with
K (Table 1).
Many studies argue that phylogenetic signal can be interpreted
as a phylogenetic heritability [12,13]. At first, this may seem
problematic because phylogenetic signal is measured for different
species, whereas heritability is defined in population genetics as the
ratio between the genetic and the phenotypic variance observed
for a trait in a given population [7]. Working on traits of infectious
diseases bridges phylogenetics and population genetics because it
involves a population of infected individuals instead of a collection
of species. This would also be the case for any phylogenetic
approach based on a phylogeny of individuals.
In order to check that there indeed is an equivalency between
the concepts of heritability and phylogenetic signal, we simulate
phylogenetic trees reflecting the evolution of a trait under an
evolutionary process with known heritability (see the Methods).
The values of K (black) and l (red) estimated on these simulated
trees strongly correlate with known heritability (Figure 2). Note
that K performs better than l when the heritability is low.
Furthermore, the variance in l is much greater, which is why we
only estimate it as a median value over many phylogenies (the
posterior tree distribution). The simulations confirm that estimat-
ing phylogenetic signal for a trait yields useful quantitative
estimates of trait heritability.
Correlation among traits
The phylogenetic comparative approach (PCA) is widely used to
study correlations among traits because taxa are not independent
and comparisons between traits should be weighted according to
the distance between taxa in the phylogeny [12–14,24,26,27].
These ideas can be applied to infection trait values.
In Table 2, we show the difference between a classical
regression between two traits and a regression that incorporates
the non-independence of the data for HIV infection traits. The
slope of the regression between spVL and dsCD4 decreases by
approximately 60% when the phylogeny is taken into account.
Furthermore, spVL does not explain much of the variance in
dsCD4 (a linear model yields an adjusted R2 of 0.047). We also
find that accounting for the non-independence of the data can
alter the significance of a correlation: the dsCD4 varies among
transmission groups with a classical test but not with a test
including the phylogeny. This provides new data to the recent
debate on the link between these two predictors of virulence (see
[28] and the resulting correspondence).
These results can appear as contradictory with our earlier result
that dsCD4 does not exhibit phylogenetic signal. The reason for the
effect of the phylogeny on regressions involving dsCD4 is that when
the PCA is used to study trait correlations, the correction applied to
the phylogeny (i.e. the value of K or l) is calculated using the value
of both traits (the model finds the covariance between trait values of
pairs of tips that best explains the data assuming a Brownian model
of evolution of the trait on the tree [26]).
Discussion
The control of the virus genome on the virulence of an HIV
infection is a controversial issue. HIV-1 is known to be more
virulent than HIV-2. Within HIV-1 group M, there is also
evidence that some subtypes are less virulent than others, e.g.
viruses from subtype A seem to be associated with slower disease
progression than viruses from subtype D [29–31]. Also, there is
experimental evidence for differences in virulence among SIV
viruses [32]. However, there is much less evidence supporting the
existence of a control of the virus genotype over the duration of the
infection within a given subtype of HIV-1. Here, we show that
even within subtype B, the set-point viral load (spVL), which
predicts HIV virulence, can be inherited from one infection to the
next thus indicating that this trait depends strongly on the virus
genotype. The validity of our approach is supported by the fact
that we find heritability values close to 1 for a trait associated with
drug resistance. Our results are statistically significant and robust
to noise in the phylogeny. This robustness is important because
HIV phylogenies tend to be inaccurate [22] due to processes such
as recombination and co-infections.
The heritability value we find is high compared to previous
studies [8–10], especially considering the fact that most (if not all)
of these studies include hosts infected by different subtypes of HIV-
1, which is likely to increase the genetical component of the
variance observed in the population and hence the heritability.
The magnitude of our estimate only compares with that of Hecht
et al. [11]. However, one should be careful with comparing the
two studies. First, they do not use spVL but the earliest measure of
viral load. It is therefore possible that their measure is not linked to
disease progression. Second, it is not clear if all the patients they
consider are infected by the same subtype of HIV, which could
increase the heritability, as explained above. Third, they include
both treated and untreated patients, whereas we only include
untreated patients. Fourth, and perhaps most important, they have
only 49 patients in their largest dataset.
Table 1. Phylogenetic signal in the 4 datasets for the three different traits.
Dataset n K for log(spVL) K for dsCD4 K for prAZT
~
l for log(spVL)
~
l for dsCD4
~
l for prAZT
MSM strict 134 0.59 n.s. 0.91 0.51 (0.27) 0 1.07 (0.12)
all strict 230 n.s. n.s. n.s. 0.17 0 0.88 (0.06)
MSM liberal 404 0.09 n.s. 0.82 0.13 (0.05) 0 1.07 (0.015)
all liberal 661 n.s. n.s. 0.71 — — —
We use two estimators (K and l) that lead to similar results. Significance code for the p-value of the randomisation test for K is ‘ ’ƒ0:001, ‘ ’ƒ0:01, ‘ ’ƒ0:05, and
‘n.s.’ indicates that the signal does not differ from that found on a random tree. The ~l are obtained by taking the median value of l over 161 trees (see the Methods). We
also show the standard deviation in brackets. ‘—’ indicates that the largest tree could not be computed with the Bayesian method because of the large number of
patients. n is the sample size of each dataset.
doi:10.1371/journal.ppat.1001123.t001
Heritability of HIV Infection Traits
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Implications of virulence heritability
An increasing number of studies attempt to estimate heritability
of HIV set-point viral load, which is a measure of virulence
[6,8–11]. The magnitude of the heritability value for spVL we find
is of clinical and epidemiological importance.
The clinical importance stems from the fact that for a trait to be
heritable from one infection to the next, there needs to be a
control from the virus genotype over the trait. In the case of HIV,
the course of the natural history of the infection is still largely not
understood. For instance, the exact role of within-host evolution in
the onset of AIDS is still unclear [33]. Here, we show that the
duration of the infection is at least partially controlled by the
genotype of the virus that infects the host. An implication is that
some of the answers to AIDS pathogenesis might be found in the
genome of the virus.
Trait heritability from one infection to the next also has
implications for evolutionary epidemiology. For natural selection
to act on a trait, three conditions must be fulfilled: the trait must be
variable in the population, it must affect the fitness of individuals
bearing it and it must be heritable (at least partially). This
reasoning can be extended to evolutionary epidemiology by
viewing an infection as an individual, and defining fitness as the
number of new infections caused [34]. In the case of HIV, spVL is
known to vary among patients [35] and to affect the infection
fitness, because viral load correlates with the transmission rate
[16,36] and the virulence [16,18,21]. Our finding that spVL is
highly heritable implies that this trait is subject to natural selection
at the between-host level, which supports the possibility that a
trade-off between virulence and transmission rate can drive the
evolution of HIV [16]. This also sheds a new light on the ongoing
debate concerning why studies have failed to provide a clear
picture of how HIV virulence evolved over the last decade (some
find that it decreased [37,38], others find that it increased [17,39–
42] and some find no significant trend [43–49]). These conflicting
trends could be explained by different dates of origin of the
pandemics and different initial values of virulence [17]. Another
possibility is that the host genotype control over virulence is
greater than that of the virus (see next paragraph). Finally, the
structure of sexual transmission networks is likely to have a strong
effect on the fitness of an infection and hence on viral evolution.
Host effects
Set-point viral load and disease progression have been shown to
be affected by host factors, especially human leucocyte antigen
(HLA) alleles [2,3,50,51]. This could introduce a bias in our results if
hosts with similar HLA alleles tend to be close in the transmission
chain. Note that this bias also occurs in studies based on
transmission pairs. Unfortunately, in the subset of the SHCS data
we used, there was not enough information about the patients to
correct for this bias. More generally, we cannot exclude correlations
between the environments in which the patients live but these effects
are likely to be smaller in our study than in studies based on known
couples because the PCA does not require patient couples.
Another potential concern is that other diseases could be
transmitted sexually with HIV that could affect trait values. The
information of the SHCS allows us to show that there is no
correlation between spVL and infection by hepatitis C, hepatitis B
or syphilis (see Supplementary Results).
Furthermore, viruses evolving in similar within-host environ-
ment (either because of similar HLA alleles or drug treatments)
might tend to evolve in a similar fashion. As a result, the proximity
in the phylogeny could indicate proximity in within-host
environment rather than proximity in the transmission chain. In
order to limit the effect of host*virus interactions, we built a
phylogeny using mutations on third codon positions only. As
shown in the Supplementary Results, the outcome of the test is
similar: K is equal to 0.52 for spVL and to 0.82 for prAZT in the
MSM strict dataset. That a phylogeny built on synonymous
Table 2. Regressions between life-history traits with and without correction for phylogenetic signal.
Traits and dataset Test Slope (SE) Y-intercept (SE) ln(likelihood) AIC
log(spVL) vs. dsCD4 (MSM strict) OLS 21.7e-3(8.1e-4) 4.26(0.08) 256 119
RegBM 22.7e-3(6.8e-4) 4.1(0.34) 257 121
Trait variation among risk groups (all liberal) OLS log(spVL) and dsCD4
RegBM log(spVL) and dsCD4n:s:
The first line is a regression between log(spVL) and dsCD4. The second line tests if values for a given trait vary across risk groups. OLS is the ordinary generalised least
square without phylogenetic correction (a generalised linear model yielded similar results); RegBM indicates a correction based on the tree assuming Brownian motion.
SE stands for ‘Standard Error’. For further details, see the Supplementary Methods. Significance code for the p-value of the test is ‘ ’ƒ0:001, ‘ ’ƒ0:01, ‘ ’ƒ0:05 and
‘n.s.’ for non sognificant.
doi:10.1371/journal.ppat.1001123.t002
Figure 2. Phylogenetic signal estimated for evolutionary
processes with known heritability. 20 phylogenies are simulated
to model the evolution of an infection trait in a case where heritability is
set to a given value. Phylogenetic signal (K in black and l in red) is then
estimated on each tree using only 128 leaves to account for incomplete
sampling. The box plot shows the median values, the three quartiles
and the outliers. The dashed line shows y~x. The slope is 0:83
(p-valuev0:001 and adjustedR2~0:89) forK and of 0:95 (p-valuev0:01
and adjusted R2~0:88) for l.
doi:10.1371/journal.ppat.1001123.g002
Heritability of HIV Infection Traits
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mutations only leads to similar results allows us to rule out
convergent evolution as a potential bias.
We do not know which proportion of the virus genotype effect is
due to the interaction between virus and host genotypes (i.e. that
some host genotypes are more sensitive to some virus genotypes).
This implies that, in theory, the host control on spVL could also be
high. A way to test this effect so that it could be compared to the
present result would be to conduct a similar approach but with a
host phylogeny instead of a virus phylogeny. The tip data would be
the same and the results would tell us what the host genotype
control over the trait is. This analysis could not be performed with
the subset of the SHCS data we used in this study because we
lacked information for many hosts. However, it might be
achievable with another subset of the SHCS data.
More speculatively, we find that, in agreement with an earlier
study [28], the correlation between spVL and dsCD4 is weak (low
R2). However, both these traits are known to be early predictors of
virulence [18,21]. A way to reconcile these two apparently
contradictory facts would be to show that spVL and dsCD4 are
both correlated with processes that add up to determine virulence.
Another way to write this is that if C~AzB, both A and B are
correlated with C but A needs not to be correlated with B. In our
case, C would be virulence and A and B pathogenic processes
linked with dsCD4 and spVL. We show that the virus has a strong
control over spVL but not over dsCD4. If dsCD4 was shown to be
strongly controlled by the host genotype, the A and B processes
that contribute to virulence could be interpreted as a virus and a
host contribution. Our results suggest that a way to better
understand the progression to AIDS could be to disentangle host
and viral contributions to virulence, which are highlighted here by
the different control of the virus over dsCD4 and spVL.
Advantages of the phylogenetic comparative approach
Some studies have used phylogenies of infections to understand
the epidemiology of infectious diseases (see [52] and references
therein). However, these studies are based on qualitative traits,
usually the presence/absence at a given location (geographically or
within a type of cells). Also, these studies use estimators to link the
phylogeny and the qualitative traits that are different from
phylogenetic signal and thus not directly associable with
heritability.
To our knowledge, our study is the first application of the
phylogenetic comparative approach (PCA) to infection quantita-
tive traits. As such, it makes it relevant to discuss the prospects of
its application to infectious diseases. The main advantage of the
PCA is that it does not require any prior knowledge about the
transmission pairs. First, this greatly increases the amount of data
accessible. Indeed, in many cohort studies, such as the SHCS,
there is no information about transmission pairs. Previous studies
estimating the heritability of spVL have 155 [9], 194 [8], 112 [10]
and 48 patients [11] in their largest dataset. Here, we have 661
patients in our largest dataset and 134 in the smallest. Having
more patient data allows us to improve the phylogeny by focusing
on MSM only. It also allows us to improve the estimation of spVL
by selecting patients for whom we have several measures of viral
load, which could explain why we detect higher signal than earlier
studies in which many spVL had to be estimated from a single
measurement [8]. Second, working without pairs reduces some of
the biases inherent to studies based on known couples (e.g. living in
the same environment). Third, it incorporates within-host
evolution through the branch length. Even though all the genetic
data we use originates from after the acute phase, the sampling
time is indirectly taken into account because a virus sampled
during chronic infection should generate longer branches in the
phylogeny than a virus transmitted early in the infection.
The PCA can also be used to study correlations among infection
traits. To our knowledge, no other study has raised the problem
that, for rapidly evolving diseases, data from different patients are
not independent and that regressions should be weighted by
distance in the transmission chain.
Finally, for most non-human diseases, standard population
genetics settings can be conducted to estimate experimentally trait
heritability. In the case of human diseases, we work with
epidemiological data. The PCA is thus especially suited to study
rapidly evolving diseases of humans.
Limitations
We were unable to detect phylogenetic signal for the log(spVL)
when we used a liberal spVL definition or when we considered all
the transmission groups. This is consistent with earlier studies that
find that restricting the dataset to improve the phylogeny [8] or the
spVL measure [10,11] greatly increases the heritability estimate.
Our interpretation is that the strict criterion we use allows us to
improve the spVL measurement (thus decreasing measurement
error) and that restricting the dataset to MSM patients yields a
more accurate phylogeny (because of a better estimation of the
transmission chain in the SHCS). Moreover, both restrictions
remove the effect of confounding factors, such as patient sex or
age, on trait values.
For completeness, we mention two alternative hypotheses to
account for the low signal value in the ‘MSM liberal’ dataset. First,
it is possible that high within-host variability in viral load
measurements is positively correlated with the amount of within-
host evolution, which itself has been shown to be linked with
disease progression [53]. In short, our strict selection criterion
might be selecting for infections with little within-host evolution.
However, this is unlikely because, as we show in the Supplemen-
tary Results, the log(spVL) is slightly higher in the strict than in the
liberal dataset. If variability in spVL was correlated with within-
host evolution, we would expect patients from the strict dataset to
have a slow disease progression (i.e. a low spVL). A possibility to
test this effect would be to vary the level of strictness of the spVL
definition. Second, it is possible that the method we use is less
efficient at detecting phylogenetic signal in trees that are too large.
In the Supplementary Results, we show that tree size could have a
slight effect on the accuracy of l, but this effect is less important
than the intensity of the signal.
As shown in Figure 2, the correlation between heritability and
phylogenetic signal is not 1 to 1. This means that, even if there is a
strong control of the virus genotype on the spVL, it is not yet
possible to say if this value is closer to 40 or 60%. Further analyses
are required to understand analytically the exact mapping between
heritability and phylogenetic signal in the case of infectious
diseases.
Finally, we built the phylogeny using the pol gene, which is the
gene routinely sequenced in the SHCS. However, using a different
gene is unlikely to affect our results: a recent study shows that
phylogenies built on clonal env sequences were almost identical to
phylogenies built on pol sequences from known transmission pairs
[54].
Perspectives
The PCA argues that HIV set-point viral load is strongly
controlled by the virus genotype. Our study can be extended by
considering other infection life-history traits (e.g. the duration of
the infection) or other infectious diseases that evolve rapidly
enough in their host for a phylogeny to be inferred. Further studies
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are also needed to identify the specificities of the application of the
comparative method to phylogenies of infectious diseases.
Nevertheless, this approach opens new perspectives for evolution-
ary epidemiology by allowing a better understanding of how
natural selection acts on infection traits. It also has the practical
advantage to be applicable to many datasets of infectious diseases
of humans because it does not require any prior knowledge of the
transmission chain.
Materials and Methods
The data
The Swiss HIV Cohort Study (SHCS) is a nationwide
prospective study based on voluntary participation of persons
infected with HIV-1. The rationale, organisation and baseline
characteristics of the study [15,55] and the drug resistance
database [56] we use have been described elsewhere in detail.
Data of 1100 patients could be incorporated in this study. Each
patient is represented only once in the data. We selected SHCS
participants infected by HIV-1 subtype B (which is the majority in
Switzerland) with a genotypic drug resistance test while still ART-
naive and with at least three HIV RNA measurements. We only
included measurements that were collected after the acute phase of
HIV infection (as described in [25]), but prior to start of ART, or
the first CDC C event, or the time when the CD4 count first drops
below 200 cells. Many HIV-infected patients in Switzerland, as in
other countries, receive their HIV diagnosis at a late disease stage
and almost immediately start HIV treatment. However, these late
presenting patients do not differ from other patients infected by
HIV-1 subtype B [57], and this is not likely to introduce a bias on
the 1100 patients we consider.
The three main transmission groups in the SHCS are
heterosexuals (HET), injection drug users (IDU) and men having
sex with men (MSM). We focused on MSM because, on the basis
of all newly reported positive HIV Tests in Switzerland between
2000 and 2006 (Federal Office of Public Health, Switzerland), we
estimate that the liberal dataset includes 25% of all newly
diagnosed MSM, as opposed to 10% for IDU and 4% for HET.
Also, a previous study has shown that patients from this
transmission group tend to cluster in phylogenetic trees [25]. In
our case, it means that the phylogeny we obtain using this
transmission group only is likely to be closer to the actual
transmission chain.
The phylogenies
For each patient, we know the RNA sequence generated by
bulk sequencing of the HIV polymerase (the pol gene). The
sequence isolated from 49 patients infected by HIV-1 subtype C
was used as an outgroup. We removed all major amino acid
positions that are strongly correlated with antiretroviral drug
resistance and built a different tree for each of the four subsets of
the dataset. In all the trees we built, the ingroup and the outgroup
were monophyletic. All phylogenies were built both with a
maximum likelihood approach and with a Bayesian approach.
The spVL
Measuring spVL often generates passionate debates. The notion
of spVL originates from the realisation that during the
asymptomatic phase of an HIV infection, the viral load remains
generally stable. The problem is that fluctuations can occur in
some patients [58]. Also, there seems to be a tendency for the viral
load to increase during the asymptomatic phase [59], which means
that defining spVL as a line (with a slope and an intercept) could
provide us with more information. Overall, the most appropriate
measurement for spVL largely depends on the data available and
on the question asked.
Having multiple viral load measures in each patient allows to
improve the quality of the spVL estimate. Some use the median
value of viral load measurements [20]. Other studies on the host
genetic control over spVL variations define spVL as the mean
log10 virus load per mL in patients and only consider cases where
all the viral load measurement fluctuate within a 0.5-log band
around the patient specific mean [2,3]. Our ‘strict’ definition of
spVL is similar except for the fact that we allow measures to
fluctuate in a 1-log band (n~230). We also consider a ‘liberal’
definition, where spVL is the mean viral load taken over at least
three consecutive viral loads, fluctuating within a 1-log band
(n~661). Note that spVL was a continuous (and normally
distributed) trait in all our datasets so that the variation we
observed are not likely to be linked to a specific allele of a gene.
The effects of patient age, sex and transmission group on the
traits we study (spVL, dsCD4 and prAZT) are described in
Supplementary Results (see also [19] for a review).
The prAZT
This trait is linked to the probability that a virus is resistant to
zidovudine (AZT) without ever having been exposed to this drug.
It is estimated from the pol sequence using the geno2pheno system
[60]. In order to remove potential correlations between this trait
and the phylogeny, we only used the positions associated with drug
resistance that we removed to build the phylogeny to estimate
prAZT. These relevant positions were inserted in a neutral
background sequence (for which there was no drug resistance).
Phylogenetic signal
Phylogenetic signal measures the extent to which the fact that
some species tend to have similar trait values can be explained
statistically by their close evolutionary history (i.e. the fact that they
share a recent common ancestor). Estimators are usually based on
Felsenstein’s method of independent contrasts [14,24]. A contrast
is the difference between two trait values of two tips of the
phylogeny, which is weighted by the distance between the tips in
the phylogeny. Mathematically, the contrast cij between two tips i
and j is given by:
cij~
Dti{tj Dffiffiffiffiffi
dij
p ð1Þ
where ti and tj are the trait values of i and j and dij is the distance
between i and j in the phylogeny.
If the variance in all the independent contrasts of a phylogeny is
low (resp. high), it means that related species tend to have similar
(resp. different) trait values. This simple approach is not entirely
satisfactory because, for instance, it does consider the fact that
specific shapes of the phylogeny can be more prone to exhibit
higher or lower values in variance of contrasts. To solve this
problem, we use two recently developed estimators.
The first estimator, K [12], is based on the mean squared error
(MSE) of the contrasts or of the terms of Pagel’s covariance matrix,
which is described below. The ratio between the MSE obtained
after transformation of the tree by a factor w (denoted MSE0) and
the MSE obtained with the real tree (denoted MSE) indicates how
well the transformed tree fits the data. K is a normalisation of this
quantity. It is obtained by dividing the ratio MSE0/MSE by the
expected ratio MSE0/MSE given the shape and size of the
phylogeny. K has the advantage of being normalised, i.e. that its
value accounts for the fact that phylogenetic signal depends on the
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shape of the phylogeny. The significance of the estimate is assessed
through a randomisation test based on a shuffling of the tip values.
The second estimator, l, was introduced by Pagel [26,61]. The
idea is to formalise the phylogeny using a single variance-
covariance matrix (denoted M), which predicts the covariance
between the traits of two tips based on their distance in the
phylogeny (i.e. how old their most recent common ancestor is) and
assuming Brownian motion. From this covariance matrix M, the
model can generate a predicted distribution of traits (a vector
Tpred) in the population (i.e. tip values). l is used to multiply the
off-diagonal terms of the matrix. It is then possible to generate a
predicted distribution of tip values that depends on l (Tpred(l)).
The phylogenetic signal is the value of l that generates the tip data
(Tpred(l)) the closest to the observed data (Tobs(l)). The fit is
estimated with a Maximum Likelihood approach. l is less robust
than K (see e.g. the variance in Figure 2), which is why we apply it
to the set of trees resulting from a Bayesian estimation of the
phylogeny and present the median value we obtain (~l). For further
details about these estimators and about their high level of
robustness, see the Supplementary Results.
The model
We simulate an evolutionary process of a trait with known
heritability values (f) on a tree to compare the performance of our
two estimators (Figure 2). We initiate the system with an ancestor
that has a trait value (x0) drawn from the empirical distribution of
traits (spVL) in the population (note however that this model is
more general and can be applied to any trait of any infectious
disease). Every new infection is modelled as a branching in the
tree: one of the new branches corresponds to the infecting
individuals and is given the trait value of the ancestor branch (xa),
whereas the other branch corresponds to the infected individual
and is given a new trait value (xaz1). This new trait is obtained
with the following rule:
xaz1~fxaz(1{f)y ð2Þ
where f is the heritability of the trait and y is a random variable
drawn from the empirical trait distribution in the population (in
the ‘liberal’ dataset). Another possibility would have been to model
explicitly the environmental and the genetical component of the
trait (as in [13]). The problem with such an approach is that it
would require the introduction of a stabilising selection model,
instead of the Brownian motion model, to describe trait evolution.
Here, the y random variable is drawn in a trait distribution, which
allows us to obtain a final set of trait values that has a mean and a
variance close to what is observed empirically.
We introduce host death events as well as incomplete sampling
of the hosts. The probability of dying was taken to be 1/3 of the
probability of transmitting (thus approximating an R0 of 3 for the
disease). We model the evolution over 13 generations and then
sample uniformly at random 128 tips for each tree. There were 20
replicates for each of the heritability values we model. K and l
were estimated for each of the replicates. The resulting trees before
sampling did not have the same size (because of the stochastic
death process) but we found no significant effect of the intensity of
sampling on the value of the estimator.
Further details about the Materials and Methods are available
in the Supplementary Methods (Text S2).
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